Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension
about
Identifying "super responders" in pulmonary arterial hypertension.Cumulative subgroup analysis to reduce waste in clinical research for individualised medicine.Update in Pulmonary Vascular Disease 2015.Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension.Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma Pulmonary Arterial Hypertension.Translational Advances in the Field of Pulmonary Hypertension Molecular Medicine of Pulmonary Arterial Hypertension. From Population Genetics to Precision Medicine and Gene Editing.Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series.Screening and Early Detection of Pulmonary Arterial Hypertension in Connective Tissue Diseases. It Is Time to Institute It!Survival of adults with systemic autoimmune rheumatic diseases and pulmonary arterial hypertension after lung transplantation.Circulating Protein Biomarkers in Systemic Sclerosis Related Pulmonary Arterial Hypertension: A Review of Published Data.
P2860
Q33788452-242E3508-C2B1-4E76-B694-4BB727E9930BQ36224020-976AA6F9-6B23-48AC-952F-E39EFE368288Q37013164-26779561-DA70-42BC-A2EF-4AAF4A14F34CQ37616946-5615B31E-78C6-44C4-8478-105175D13F57Q38403596-7ACFB3F4-6811-4A52-AB80-EA053DA2E95AQ38914965-8B0FEAD5-AAF5-4682-AEBE-2D7F8F023656Q41146142-7E419482-6A85-4BBE-8F83-68F8DB3FED57Q41356862-5060E0E2-91EB-4E8B-B066-DA239209F010Q44970403-9DE8E5BD-3EA7-4E66-B85D-4ED99AC04E2DQ47108856-B37FA581-F448-4EB2-A342-693011FEAAF5Q47845345-ECEE42C0-1DAB-4584-8F33-B23C03FC94D5Q47975605-56BB1AD1-4900-4417-BD04-6EC3A979C90DQ49977641-0D3CF272-8152-4C1E-8B83-F2DB5212600BQ55285033-9F803C41-988F-493B-83BC-C7E7B7749190
P2860
Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Comparison of Treatment Respon ...... ulmonary Arterial Hypertension
@ast
Comparison of Treatment Respon ...... ulmonary Arterial Hypertension
@en
type
label
Comparison of Treatment Respon ...... ulmonary Arterial Hypertension
@ast
Comparison of Treatment Respon ...... ulmonary Arterial Hypertension
@en
prefLabel
Comparison of Treatment Respon ...... ulmonary Arterial Hypertension
@ast
Comparison of Treatment Respon ...... ulmonary Arterial Hypertension
@en
P2093
P2860
P1476
Comparison of Treatment Respon ...... ulmonary Arterial Hypertension
@en
P2093
Amy Praestgaard
Nicole B Gabler
Peter A Merkel
Rennie L Rhee
Sapna Sangani
Steven M Kawut
P2860
P304
P356
10.1164/RCCM.201507-1456OC
P407
P577
2015-08-20T00:00:00Z